BioCentury
ARTICLE | Company News

InterMune, MoliChem deal

May 14, 2001 7:00 AM UTC

The companies will jointly develop and market worldwide MLCM’s Moli1901 duramycin compound to treat pulmonary diseases. MLCM will receive a $1.5 million upfront payment plus milestones. ITMN and MLCM ...